Plain-English translation of NCT04608630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
When you spend time in intensive care, your bones can weaken quickly—even during your hospital stay. This trial is testing whether two medications called Denosumab and Zoledronic acid can prevent this bone loss and reduce your risk of fractures in the months and years after you leave the ICU. The study will compare these treatments to a placebo (an inactive injection) to see which works best.
Patients who survive critical illness—especially women over 50 and men over 70—lose bone density rapidly and have much higher rates of broken bones after leaving the hospital. Currently, there is no standard treatment to prevent this complication, so researchers want to test whether this medication can protect bone health during this vulnerable time.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will randomly receive either Denosumab (an injection under the skin on day 1 and again 6 months later), Zoledronic acid (an IV infusion on day 1 only), or a placebo. You will also have bone density scans to measure changes in your bone strength over time. Your participation will involve visits to the hospital and follow-up assessments to track whether the treatment helps prevent bone loss.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Australia